Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384852 · ClinicalTrials.gov registry record · Phase 2
A Study of rhBMP-2/CPM in Closed Fractures of the Humerus
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT00384852 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 139 participants.
The verdict
NCT00384852, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess whether fracture union is accelerated in subjects with humeral fractures (proximal,diaphyseal) treated with conservative therapy (standard of care) and a single dose of rhBMP-2/CPM compared to subjects who receive standard of care alone.
Interventions
- DRUG rhBMP-2/CPM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384852
The ClinicalTrials.gov registry entry for NCT00384852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhBMP-2/CPM is the first listed.
NCT00384852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384852 about?
NCT00384852 is a clinical study titled "A Study of rhBMP-2/CPM in Closed Fractures of the Humerus". The primary objective of this study is to assess whether fracture union is accelerated in subjects with humeral fractures (proximal,diaphyseal) treated with conservative therapy (standard of care) and a single dose of rhBMP-2/CPM compared to subjects who receive standard of care alone.
What is the current status of trial NCT00384852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2007-01. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00384852?
The interventions under investigation include: rhBMP-2/CPM (DRUG).
Who is sponsoring clinical trial NCT00384852?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.